Immutep is developing novel immunotherapies for autoimmune diseases using IMP761, which functions as a LAG-3 agonist antibody.
1 report, 0 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Immutep is developing novel immunotherapies for autoimmune diseases using IMP761, which functions as a LAG-3 agonist antibody.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Immutep
Biotechnology company
Coverage
Newest first; wire copies grouped- Unknown outlet